India drug business stumbles

India is a source for a goodly amount of the world's generic drugs - there are some large and serious companies there, with a lot of expertise. And in recent years, they've just been getting larger and more serious all the time, which makes a couple of recent news items very disturbing reading.


First off, Ranbaxy Laboratories has been notified by the FDA that all of their drug applications are all now on hold, because they've found evidence that the company has submitted falsified data. Most of the problems seem to have been with stability tests, where a company takes production batches of their drugs and ages them at room temperature (and in heated chambers) to make sure that they don't break down in any unusual way on storage. Ranbaxy seems to have cut some corners: for one thing, many samples were found to have been stored in refrigerators after their testing period, some of them for extended periods. None of this was disclosed to the FDA, and closer inspection showed many more inconsistencies in the submitted data. Ranbaxy was warned about this in 2006, but followup checks showed things like employee sign-offs from people who weren't there, different test results for what were supposed to be the same samples, and the like. The FDA's letter can be read here (as a PDF), and they're clearly unhappy.

Adding to the bad publicity, another one of the big Indian companies (Dr. Reddy's) has been involved in a very unusual dispute in a well-respected chemical journal. They'd published a new procedure to make an off-patent antidepressant, but the scientists at Lundbeck, the Danish company that developed the original drug, cried foul. The Indian paper included procedures, they said, that they'd already proved were impossible, and they quoted extensive data to back up their claims. The journal took the unusual step of publishing the Lundbeck challenge, a response from the Dr. Reddy's team, and a counter-response from the Lundbeck group. Most chemists who've read the papers agree that Lundbeck won their case handily, and that the Dr. Reddy's team did not come out looking very good at all.

So it wasn't a good week for the Indian chemical industry, not at all - and it wouldn't be a good one for any country that's trying to build its reputation for reliability and quality. How much this is going to hurt India's rise in the pharma world isn't clear yet. But it sure isn't going to help.

Presented by

Derek Lowe

Derek Lowe is a drug discovery chemist with 20 years of experience in the pharmaceutical industry, which is still very much his day job. He's worked on projects targeted at Alzheimer's, cancer, diabetes, infectious diseases, and other areas, but like most discovery scientists in the business, he has yet to produce a marketed drug. Explaining how and why this happens is what led to the launch of his blog, "In the Pipeline", in 2002, and the explaining continues. . .

Saving the Bees

Honeybees contribute more than $15 billion to the U.S. economy. A short documentary considers how desperate beekeepers are trying to keep their hives alive.

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.

blog comments powered by Disqus

Video

How to Cook Spaghetti Squash (and Why)

Cooking for yourself is one of the surest ways to eat well.

Video

Before Tinder, a Tree

Looking for your soulmate? Write a letter to the "Bridegroom's Oak" in Germany.

Video

The Health Benefits of Going Outside

People spend too much time indoors. One solution: ecotherapy.

Video

Where High Tech Meets the 1950s

Why did Green Bank, West Virginia, ban wireless signals? For science.

Video

Yes, Quidditch Is Real

How J.K. Rowling's magical sport spread from Hogwarts to college campuses

Video

Would You Live in a Treehouse?

A treehouse can be an ideal office space, vacation rental, and way of reconnecting with your youth.

More in Business

Just In